Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus SEPTRA GRAPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus SEPTRA GRAPE.
COR-OTICIN vs SEPTRA GRAPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Septra Grape (trimethoprim/sulfamethoxazole) inhibits bacterial folic acid synthesis via sequential blockade: sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
1-2 drops in each affected ear twice daily for 7 days.
160 mg trimethoprim / 800 mg sulfamethoxazole (1 double-strength tablet) orally every 12 hours.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Trimethoprim: 8-10 hours (renal impairment >24h). Sulfamethoxazole: 10-13 hours (acetylation phenotype; prolonged in renal impairment). Clinical: Dosing interval generally 12h; adjust CrCl <30 mL/min.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal: 50-70% unchanged (trimethoprim), 30-50% as N-acetyl metabolite; sulfamethoxazole: 70-80% as metabolites, 20-30% unchanged; biliary excretion minimal (<5% total).
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic